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Abstract
Background: There is an urgent need for improved vaccines to protect against tuberculosis. The currently available
vaccine Bacille Calmette-Guerin (BCG) has varying immunogenicity and efficacy across different populations for
reasons not clearly understood. MVA85A is a modified vaccinia virus expressing antigen 85A from Mycobacterium
tuberculosis which has been in clinical development since 2002 as a candidate vaccine to boost BCG-induced
protection. A recent efficacy trial in South African infants failed to demonstrate enhancement of protection over
BCG alone. The immunogenicity was lower than that seen in UK trials.
The enzyme Indoleamine 2,3-dioxygenase (IDO) catalyses the first and rate-limiting step in the breakdown of the
essential amino acid tryptophan. T cells are dependent on tryptophan and IDO activity suppresses T-cell
proliferation and function.
Methods: Using samples collected during phase I trials with MVA85A across the UK and South Africa we have
investigated the relationship between vaccine immunogenicity and IDO using IFN-γ ELISPOT, qPCR and liquid
chromatography mass spectrometry.
Results: We demonstrate an IFN-γ dependent increase in IDO mRNA expression in peripheral blood mononuclear
cells (PBMC) following MVA85A vaccination in UK subjects. IDO mRNA correlates positively with the IFN-γ ELISPOT
response indicating that vaccine specific induction of IDO in PBMC is unlikely to limit the development of vaccine
specific immunity. IDO activity in the serum of volunteers from the UK and South Africa was also assessed. There
was no change in serum IDO activity following MVA85A vaccination. However, we observed higher baseline IDO
activity in South African volunteers when compared to UK volunteers. In both UK and South African serum samples,
baseline IDO activity negatively correlated with vaccine-specific IFN-γ responses, suggesting that IDO activity may
impair the generation of a CD4+ T cell memory response.
Conclusions: Baseline IDO activity was higher in South African volunteers when compared to UK volunteers, which
may represent a potential mechanism for the observed variation in vaccine immunogenicity in South African and
UK populations and may have important implications for future vaccination strategies.
Trial registration: Trials are registered at ClinicalTrials.gov; UK cohort NCT00427830, UK LTBI cohort NCT00456183,
South African cohort NCT00460590, South African LTBI cohort NCT00480558.
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Background
Tuberculosis (TB) poses an increasing global health threat,
with about 10 million new cases and 1.7 million deaths an-
nually (WHO Global Tuberculosis report) [1]. Most of the
global TB burden is borne by the developing world, with
86% of cases occurring in South-East Asia, Africa and the
Western Pacific. With the emergence of multi-drug resist-
ant strains of Mycobacterium tuberculosis (MTB) and the
spread of HIV, there is an even greater need for an im-
proved vaccine. Mycobacterium bovis Bacille Calmette-
Guerin (BCG) is the only vaccine currently available
against TB. Although BCG confers reliable protection
against disseminated TB during childhood [2,3], protec-
tion against adult pulmonary disease varies considerably
with geographical location [4].
A similar population-dependent variability in vaccine
immunogenicity has been noted with several other vac-
cines [5-7]. Here we report lower vaccine-specific IFN-γ
ELISPOT responses in South African adults when com-
pared with UK adult volunteers following administration
of the TB vaccine candidate MVA85A. MVA85A is a re-
combinant strain of modified vaccinia virus Ankara ex-
pressing the immunodominant mycobacterial antigen
85A (Ag85A) from MTB. MVA85A has proven to be
both safe and immunogenic [8-11]. However, in a recent
phase IIb efficacy trial in South African infants immuno-
genicity was modest and there was no significant protec-
tion from clinical disease [11]. In this study we have
investigated the relationship between vaccine immuno-
genicity and the enzyme Indoleamine 2,3-dioxygenase
(IDO) in different populations.
IDO catalyses the first and rate-limiting step in the
breakdown of the essential amino acid tryptophan (L-Trp)
into kynurenine (L-Kyn) and other downstream metabo-
lites [12]. IDO is expressed intracellularly in a constitutive
or inducible manner in most non-hepatic cell types, pre-
dominantly in the lungs and placenta [13]. Induction is
seen in response to various stimuli including IFN-α/β and
bacterial lipopolysaccharide, but the most potent inducer
is gamma interferon (IFN-γ) [14,15].
Since it was established that IDO is instrumental in
the maintenance of maternal-foetal tolerance by T-cell
suppression [16], there has been a growing body of re-
search on its immunoregulatory effects. L-Kyn and other
catabolites produced through the action of IDO have
been implicated in the suppression of T-cell proliferation
and induction of apoptosis [17,18]. Furthermore, IDO
expression has been shown to induce regulatory T cells
[19] and inhibit natural killer cells [20].
We hypothesised that levels of IDO may be relevant to
MVA85A vaccine immunogenicity as several studies
have indicated a role for the enzyme in mycobacterial in-
fection and disease [21,22]. IDO activity in mice in-
creases following MTB infection in an IFN-γ dependent
manner [15]. Furthermore, IDO is important in protec-
tion of the granuloma from T-cell attack [23], and is in-
duced following BCG vaccination in mice [24]. It was
anticipated that IDO expression and activity might simi-
larly be increased following vaccination with MVA85A.
We demonstrate an IFN-γ dependent increase in IDO
mRNA expression in PBMC following MVA85A vaccin-
ation. IDO mRNA correlates positively with the IFN-γ
ELISPOT response indicating that vaccine specific in-
duction of IDO in PBMC is unlikely to limit the devel-
opment of antigen specific immunity.
IDO activity in the serum of volunteers from the UK
and South Africa was also assessed. There was no
change in serum IDO activity following vaccination with
MVA85A. However, we saw higher baseline IDO activity
in South African volunteers when compared to UK vol-
unteers. This higher IDO activity was unlikely due to la-
tent TB infection as IDO activity was lower in both
latently TB infected (LTBI) and uninfected UK adults
when compared to South African adults. In both UK
and South African adults, baseline serum IDO activity
negatively correlated with vaccine-specific IFN-γ re-
sponses. The strongest correlation was observed be-
tween serum IDO at baseline and the magnitude of the
ELISPOT response 6 months following immunisation,
indicating that IDO activity may impair the generation
of a CD4+ T cell memory response.
Methods
Ethics statement
UK participants were recruited under protocols approved
by the Oxfordshire Research Ethics Committee (OxREC).
South African participants were recruited under a proto-
col approved by the Medicines Control Council of South
Africa, the Human Research Ethics Committees of the
University of Cape Town (Cape Town, South Africa) and
the Oxfordshire Research Ethics Committee (OxREC).
Written informed consent was obtained from all indi-
viduals prior to enrolment in the trials. Trials were con-
ducted according to the International Conference on
Harmonization - Good Clinical Practice guidelines and
are registered at ClinicalTrials.gov.
Peripheral blood mononuclear cells (PBMC) were iso-
lated from buffy coats from healthy PPD positive donors
(National Blood Service, Bristol), protocols approved by
the Oxfordshire Research Ethics Committee (OxREC).
Study design and participants
All participants received 5 × 107 plaque forming units
(PFU) of MVA85A (Table 1). Participants in all groups
were 18 to 50 years of age and seronegative for HIV,
hepatitis B and hepatitis C viruses. All participants were
previously BCG vaccinated.
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Participants were either negative by ex vivo ELISPOT
assay for ESAT-6 and CFP-10 or latently infected with
MTB (LTBI). Volunteers in the LTBI groups were healthy
adults, most of whom had been BCG vaccinated (Heaf test
grade II-IV, TST induration ≥10 mm) and LTBI was con-
firmed by an IFN-γ ELISpot response to the M.tb specific
antigens ESAT-6 and CFP-10 of >50SFC/million. Partici-
pants had normal chest radiographs and no clinical evi-
dence of TB disease.
Immunological assays
Immune responses were measured by ex vivo IFN-γ ELI-
SPOT assay with freshly isolated PBMC as previously de-
scribed [9]. PBMC (0.3 × 106 per well) were cultured for
18 hours with 8 pools of Ag85A peptides (10 μg/ml each
peptide) overlapping by 10 amino acids (Pathan [25]). The
Ag85A peptide specific IFN-γ ELISPOT data used in this
study has been previously reported by others [8-10,26].
Cell culture
For the measurement of IDO mRNA expression 5 × 105
freshly thawed PBMCs from trial volunteers were stimu-
lated for 16 hours with 85A peptides or media alone.
For blocking experiments PBMC were cultured with or
without the addition of 10 μg/ml anti-IFN-γ or 10 μg/ml
recombinant human IFN-γ (BD Biosciences). CD14+
cells were depleted from buffy coat PBMC from PPD+
donors using CD14 labeled magnetic beads (Invitrogen).
IDO mRNA quantification by real time PCR
Half a million freshly thawed PBMCs from trial volun-
teers were stimulated for 16 hours with Ag85A peptides
or media alone. Cells were then pelleted and RNA ex-
tracted using the RNeasy Minikit (Qiagen) according to
the manufacturer’s instructions. Reverse transcription re-
action was performed immediately following extraction
with 10 μl of RNA extract using oligo-dT (Eurofins
MWG Operon) and the Omniscript Kit (Qiagen). RNase
inhibitor, 10 U/μl, (Applied Biosciences) was added to
the reactions, which were then incubated for 60 minutes
at 37°C. Quantitative PCR (qPCR) was performed with
1 μl of cDNA using QuantiTect mastermix (Qiagen) and
10 pmol/μl of the respective forward and reverse primers
designed using PrimerQuest (Integrated DNA Technolo-
gies) and ordered from Eurofins MWG Operon. The de-
signed primers were as follows:
HPRT (F:TATGGACAGGACTGAACGTC and
R:CTACAATGTGATGGCCTCCC)
IDO (F:CTGCTGGTGGAGGACATG and
R:CACAGGAAGTTCCTGTGAG)
qPCR was performed using a Roche LightCycler 480
with the following cycling conditions: initial activation for
15 minutes at 95°C followed by 55 cycles of 15 seconds at
95°C, 20 seconds at 60°C, and 20 seconds at 72°C. PCR
products of known concentrations (106 to 101 mRNA
copies) were used for the generation of a standard curve
for each PCR plate. Analysis was performed with Roche
LightCycler 480 software and Ct values were used for
conversion to mRNA copy number according to the
standard curves. Melting curves were calculated to ex-
clude non-specific binding or primer-dimer formation.
Liquid chromatography-mass spectrometry
For the measurement of serum IDO activity 5 μl 0.1%
formic acid (Sigma Aldrich) containing 30 μg/ml of the
internal standard L-Trp-(indole-d5) (d5-Trp) (GK Gas
Products Ltd) was added to 100 μl participant serum,
and incubated with 140 μl acetonitrile and 160 μl metha-
nol (both Fisher Scientific) for 20 minutes at −20°C.
Samples were then centrifuged at 14000 g for 10 minutes
at 4°C and the supernatant removed and vacuum dried.
The lyophilised samples were re-suspended in 52.5 μl
0.1% formic acid and centrifuge filtered at 14000 g for
30 minutes at 4°C (10 kDa microcentrifuge filter, Milli-
pore). The filtrate was transferred to 0.3 ml autosampler
vials for analysis. A set of four mixed standards was pre-
pared in 0.1% formic acid using twofold serial dilutions
of L-Trp (50 μg/ml) and L-Kyn (2.5 μg/ml) (both Sigma-
Table 1 Demographics of study participants
Trial registration number NCT00427830 NCT00456183 NCT00460590 NCT00480558
Country UK UK South Africa South Africa
No of participants 11 11 10 12
LTBI - + - +
History of BCG + +/− +/− +/−
Dose of MVA85A 5 × 107 PFU 5 × 107 PFU 5 × 107 PFU 5 × 107 PFU
Age, median (range) 27 (21–54) 30.5 (20–49) 35.5 (20.7–48.7) 36 (27–49)
Gender, % male 39 83 33.3 75
serum samples available, week (number) 0 (10), 1 (5), 4 (8) 0 (10), 1 (6), 4 (10) 0 (10), 1 (10) -
PBMC samples available, week (number) 0 (8), 1 (9), 4 (9) - - -
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Aldrich), and containing 2 μg/ml of the d5-Trp internal
standard. External standards were run every 10 samples
and four-point calibration curves constructed for each
set of samples using the mean values from multiple
readings across that trial.
Samples were injected into an Acclaim Pepmap 100
c18 1.0 mm × 150.0 mm column (Thermo) using an
Ultimate 3000 nano HPLC pump (Dionex) to generate a
post-split flow rate of 3 μl/min. For the first 3.5 minutes,
the mobile phase was held at 2% acetonitrile in 2%
aqueous formic acid (A). A second solvent mixture
(B) containing 2% formic acid in acetonitrile was added,
increasing gradually in percentage until 17.5 minutes,
when it was held at 80% for 7 minutes at a flow rate of
3 μl/ min for the separation. The column eluent was di-
rected to the electrospray ion source of a HCT Ultra ion
trap mass spectrometer (capillary 4 kV, skimmer 40 V,
desolvation 300°C, nebulizer 10 psi, drying gas 5 l/min)
(Bruker Daltonics). The helium collision gas was at
4 × 10−6 Bar, and spectra were acquired in multiple reac-
tion monitoring mode. For the measurement of L-Trp
and L-Kyn, the m/z 205 and m/z 209 precursor ions re-
spectively were selected and fragmented at an amplitude
of 1.0 (arbitrary units) to produce monitored product
ions at m/z 188 for L-Trp and m/z 192.2 for L-Kyn. For
the measurement of the internal standard d5-Trp, the
m/z 210 precursor ion was isolated and fragmented, pro-
ducing a product ion at m/z 192.1, which was then fur-
ther fragmented to produce a monitored product ion at
m/z 150. The complete cycle time was 32.2 minutes.
The relative abundance of L-Trp and L-Kyn in the sam-
ples was calculated by dividing the MS peak area of the
monitored ion by the peak area of the internal standard
and converted to a concentration using the external
standard curves.
Statistical analysis
The Mann–Whitney test was used for comparison of
median values between groups for IDO mRNA expres-
sion. The Wilcoxon Signed-Rank test was used for com-
parisons of IDO activity between time points, and two-
tailed Spearman’s Rank Correlation analyses were used
to identify correlations between IDO mRNA, IDO activ-
ity and fresh IFN-γ ELISPOT data gathered at the time
of the clinical trials. p < 0.05 was considered to be statis-
tically significant. Analysis was performed using the soft-
ware Prism 5 (GraphPad Software Inc, CA) and SPSS
20.0 for Windows (SPSS Inc, Chicago, IL).
Results
MVA85A shows reduced immunogenicity in South African
adults
We have previously shown that the immunogenicity to
MVA85A is not altered by LTBI status within a population,
either UK or South African [10,26]. Data from non-LTBI
and LTBI UK populations was therefore combined in to
one UK cohort (n = 22) and compared with one com-
bined South African cohort (n = 22). Antigen specific
IFN-γ ELISPOT responses to Ag85A overlapping peptide
pools were measured 0–24 weeks following vaccination
with MVA85A. Immune responses were significantly
lower in South African adults at weeks 1, 4 and 24
following vaccination with MVA85A (Mann Whitney
Test P < 0.05 or P < 0.005) (Figure 1A). All adults had a
history of BCG vaccination and there was an equivalent
proportion of LTBI in each cohort (Table 1).
The total immune response following vaccination with
MVA85A is lower in South Africa when compared to
the UK. Area under the curve (AUC) of the IFN-γ ELI-
SPOT response to Ag85A peptides from 0–24 weeks
was calculated for each volunteer and AUC values for
each volunteer were plotted by group. The median
AUC response was significantly lower in South Africa
when compared to the UK (Mann Whitney Test P < 0.05)
(Figure 1B).
IDO mRNA production correlates with IFN-γ response to
MVA85A in UK adults, is produced by CD14+ monocytes
following vaccination with MVA85A and is dependent on
IFN-γ
We performed quantitative real time PCR analysis to
measure the expression of IDO mRNA in PBMC from
MVA85A vaccinated adults. PBMC from UK subjects
vaccinated with MVA85A were cultured with Ag85A
peptides or media only and the fold increase in IDO
mRNA expression over time was determined for each
subject. Ag85A-induced IDO mRNA expression was sig-
nificantly greater at weeks 1 and 4 when compared to
week 0 (Wilcoxon P < 0.05) (Figure 2A).
The increase in IDO mRNA expression correlated
positively with the magnitude of the IFN-γ ELISPOT re-
sponse following vaccination with MVA85A (Figure 2B).
The peak induction of IDO mRNA was observed 4 weeks
following immunisation with MVA85A. PBMC isolated
4 weeks following MVA85A vaccination were cultured
with recombinant human (rh) IFN-γ, Ag85A peptides or
Ag85A peptides and anti-IFN-γ antibodies and the fold
change in expression in stimulated compared to un-
stimulated PBMC was determined. Recombinant human
IFN-γ and Ag85A peptide stimulation induced the ex-
pression of IDO mRNA. Co-culturing cells with Ag85A
peptides and anti-IFN-γ antibodies resulted in a signifi-
cant reduction of Ag85A specific IDO mRNA expression
(Figure 2C). CD14+ magnetic beads were used to deplete
monocytes from the PBMC of 5 PPD positive donors.
IDO expression was enriched in the CD14+ fraction and
depleted when CD14+ cells were removed indicating
that CD14+ monocytes are a major source of IDO
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mRNA production in PBMC cultured with mycobacte-
rial antigens (Figure 2D).
IDO activity in serum at baseline is higher in South
African than UK volunteers
We used LC-MS to determine L-Trp and L-Kyn levels
in the stored sera of UK and South African adults. For
the UK volunteers, assays were performed on samples
from baseline (pre-vaccination), and weeks 1, 2 and 4
post-vaccination. For the South African group, serum
was only available from baseline (pre-vaccination) and
week 1 post-vaccination. IDO activity was calculated as
the ratio of L-Kyn to L-Trp (Figure 3A). There were no
statistically significant differences in levels of L-Trp, L-Kyn
or IDO activity pre- and post-vaccination in any individual
group, or when all data was combined (Figure 3B).
Although there was no vaccine related change in IDO ac-
tivity, the baseline serum IDO activity in South African
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Figure 1 The immune response following vaccination with MVA85A is lower in South African than UK adults. Antigen specific IFN-γ
ELISPOT responses to Ag85A overlapping peptide pools 0–24 weeks following vaccination with MVA85A are shown. A) MVA85A vaccinated adults
(red = South African, blue = UK), n = 22 subjects per time point. *indicates a significant difference in response between UK and South Africa at the
indicated time point (Mann Whitney Test *P < 0.05, **P < 0.005). B) The total immune response following vaccination with MVA85A is lower in
South Africa when compared to the UK. Area under the curve (AUC) of the IFN-γ ELISPOT response to Ag85A peptides from 0–24 weeks was
calculated for each volunteer. AUC values for each volunteer were then plotted by group (red = South African, blue = UK) n = 22 subjects per
group. *indicates significant difference from week 0 (Mann Whitney Test P < 0.05).
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volunteers was higher than that of the UK volunteers
(p = <.05, Mann Whitney) (Figure 3B).
IDO activity in serum is negatively correlated with the
magnitude of the IFN-γ ELISPOT response following
vaccination with MVA85A
We correlated IDO activity in serum with ex vivo 85A
peptide specific IFN-γ ELISPOT responses. In both UK
and South African populations IDO activity in the serum
was negatively correlated with IFN-γ ELISPOT re-
sponses with the strongest correlations seen with IFN-γ
ELISPOT responses measured at 4 and 24 weeks (p < .05
and P < .005, Spearman’s) (Figure 4A and B). The rela-
tionship between serum IDO activity and the long term
ELISPOT response suggests that serum IDO activity
may impair the development of a long-term, T cell mem-
ory response to Ag85A.
Discussion
Immune responses to MVA85A were higher in UK adults
than South African adults regardless of LTBI status. There
was a similar age and gender distribution among the co-
horts and all adults were screened to be seronegative for
HIV, hepatitis B and hepatitis C. We have previously
shown that TGF-β1, regulatory T-cells and TLR-1 expres-
sion are correlated with the magnitude of the T-cell re-
sponse to MVA85A in UK adults [27-29]. In this study we
have investigated the relationship between vaccine im-
munogenicity and the enzyme IDO. As MVA85Ax in-
duces potent IFN-γ responses [9], we hypothesised that
IDO mRNA would be increased following MVA85A vac-
cination. In UK adults we observed an increase in IDO
mRNA expression at weeks 1 and 4 post-vaccination com-
pared to baseline. IDO mRNA was induced by IFN-γ in
CD14+ cells following stimulation of PBMC with Ag85A
BA
DC
Figure 2 IDO mRNA following MVA85A vaccination is produced by CD14+ monocytes and dependent on IFN-γ stimulation. A) PBMC
from BCG vaccinated subjects boosted with MVA85A were cultured with 85A peptides or media only and the fold increase in IDO mRNA
expression over time was determined for each subject (n = 8). Ag85A-induced IDO mRNA expression was significantly greater at weeks 1 and 4
when compared to week 0 (Wilcoxon *P < .05). B) The increase in IDO mRNA expression correlated with the IFN-γ ELISPOT response (data from
week 1 following MVA85A) (Spearman’s correlation P < .05, r = 0.79). C) PBMC from BCG vaccinated subjects boosted 4 weeks previously with
MVA85A were cultured with recombinant human (rh) IFN-γ, 85A peptides or 85A peptides and anti-IFN-γ antibodies and the fold change in
expression in stimulated compared to unstimulated PBMC was determined (n = 5). Recombinant human IFN-γ and 85A peptide stimulation
induced the expression of IDO mRNA. Co-culturing cells with 85A peptides and anti-IFN-γ antibodies resulted in significant reduction of 85A
specific IDO mRNA expression (Wilcoxon *P < .05). D) CD14+ magnetic beads were used to deplete monocytes from total PBMC. IDO expression
was enriched in the CD14+ fraction and depleted when CD14+ cells were removed (n = 5). Mann Whitney was used for comparison between
groups (**P < .005).
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peptides. To determine if IDO in PBMC could limit the
magnitude of the immune response to MVA85A we corre-
lated the increase in IDO mRNA with the Ag85A peptide
specific IFN-γ ELISPOT response. IDO mRNA increase
correlated positively with the IFN-γ ELISPOT response,
suggesting that following vaccination with MVA85A, IDO
from CD14+ cells does not limit the secretion of IFN-γ
from T-cells.
We then went on to investigate IDO activity in the
serum of UK and South African adults using LC-MS. IDO
activity in the serum did not change following vaccination
with MVA85A, which may be a result of the transient
effect of the vaccine; the MVA vector is non-replicating
and does not persist in the host and systemic effects
are usually undetectable 24–48 hours after immuni-
sation [13,25].
Although we did not observe a change in serum IDO
activity due to vaccination we did see higher baseline
IDO activity in the serum of South African adults com-
pared with adults from the UK. This higher IDO activity
was unlikely to be due to latent TB infection as IDO ac-
tivity was lower in both LTBI and uninfected UK adults
when compared to South African adults. Active TB
patients have increased activity of serum IDO [22],
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Figure 3 Serum IDO activity is higher in South African compared to UK adults. A) Serum IDO activity was measured in serum using LC-MS
to quantity L-Trp and L-Kyn in participant serum. The ratio of L-Trp/L-Kyn gives a measure of IDO enzyme activity in host serum. B) IDO activity
was assessed in serum from UK and South African adults at baseline (pre-vaccination, week 0) and 1 week following immunisation with MVA85A.
Mann Whitney was used for comparison between groups (*P < .05).
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however, we saw no difference in IDO activity by LTBI
status, indicating that IFN-γ secretion in response to
ESAT-6 and CFP-10 (used here to define LTBI) does not
necessarily reflect chronic exposure to MTB or that the
exposure is below the threshold required to see a change
in systemic IDO activity.
In addition to TB there are other chronic infectious
and non-infectious diseases which stimulate the produc-
tion of IFN-γ and could induce IDO activity. In a recent
study of the yellow fever vaccine YF-17D in volunteers
from Uganda and Switzerland, Ugandan volunteers dem-
onstrated higher frequencies of exhausted and activated
NK cells, differentiated T and B cells, and proinflamma-
tory monocytes at baseline, indicating immune activation
[30]. Furthermore, a study of Malawian and UK adoles-
cents showed that Malawian volunteers had a lower
percentage of naïve T cells and higher percentage of
antigen-experienced T cells and CMV seroprevalence
compared with age-matched UK volunteers. The authors
conclude that this difference is likely to reflect a greater
natural exposure to various infections in the African en-
vironment [31]. It may be that a similar effect present in
South African volunteers results in constitutively higher
levels of IDO activity.
We investigated the relationship between serum IDO
activity and the MVA85A vaccine-specific IFN-γ ELI-
SPOT response. Higher IDO activity at the time of
MVA85A vaccination is correlated with lower vaccine
specific IFN-γ T-cell responses at both 4 and 24 weeks
following immunisation, and these are also the time
points at which we see the greatest difference in immune
response between UK and South African adults
(Figure 1). Although the peak effector response to
MVA85A is observed 1 week following immunisation, the
peak proliferative response is seen at week 24 [32]. IDO
has been shown to inhibit both T cell proliferation and the
generation of a T cell memory response and it is the
longer-term memory response to MVA85A which is most
correlated with IDO activity in the serum [17,33]. In the
yellow fever vaccine study described above, Ugandan vol-
unteers showed an impaired vaccine response compared
with Swiss volunteers, and this was associated with mea-
sures of immune activation at baseline [30].
It is possible that variation in serum IDO activity be-
tween populations may also account for variations in the
immunogenicity and efficacy of BCG and other T-cell
inducing vaccines. Manipulation of this pathway could
thus be used to improve vaccine efficacy in endemic
countries. There is currently interest in developing IDO
inhibitors for the treatment of cancer which may have
potential application in vaccination, in particular thera-
peutic vaccination, as TB patients have high levels of
IDO activity. Another strategy is to target the IDO en-
zyme through boosting of naturally occurring T-cell re-
sponses directed against IDO epitopes [34] or silencing
of the IDO gene [35].
Conclusions
Using serum and PBMC collected during a series of
phase I trials with MVA85A we have shown that IDO
activity in the serum is correlated with the magnitude of
the immune response to MVA85A. High baseline IDO
activity, possibly resulting from chronic immune activa-
tion, could act to reduce IFN-γ ELISPOT responses by
limiting T cell proliferation and the development of
CD4+ T cell memory. The role of IDO-mediated sup-
pression in vaccine induced immunity warrants further
investigation.
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Figure 4 Serum IDO activity is negatively correlated with the
85A peptide specific IFN-γ ELISPOT response. IDO activity at
baseline for both UK and South African volunteers was correlated
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